首页> 美国卫生研究院文献>Journal of the Endocrine Society >MON-516 Quantitative Analysis of Differential Enigma/PDLIM7 Gene Expression in Thyroid Cancer vs. Benign Nodules
【2h】

MON-516 Quantitative Analysis of Differential Enigma/PDLIM7 Gene Expression in Thyroid Cancer vs. Benign Nodules

机译:Mon-516甲状腺癌中差分enigma / pdlim7基因表达的定量分析与良性结节

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thyroid cancer incidence is rising worldwide. Although fine-needle aspiration biopsy (FNAB) is an accurate modality for evaluating thyroid nodules, up to 25% of FNABs still yield indeterminate results. There is a considerable number of diagnostic thyroidectomies for benign disease as a result of indeterminate FNAB. A more accurate and time-efficient diagnostic approach for analyzing indeterminate thyroid nodules may reduce diagnostic thyroidectomy. Recently, the osteogenic protein, Enigma, has been associated with different cancer types, including thyroid cancer progression and calcification through its interaction with bone morphogenic protein-1 (BMP-1), and tyrosine kinases linked to mitogenic signaling pathways [1, 2]. Our published data on Enigma protein analysis with immunohistochemistry showed promising results in discriminating between malignant versus benign thyroid nodules and demonstrated a correlation with thyroid cancer staging [3]. In this study, we are investigating Enigma at a gene expression level by real-time (RT-qPCR), which is a quantitative and more time-efficient method that requires smaller samples (FNA) than immunohistochemistry. We analyzed Enigma mRNA expression levels to determine if Enigma-qPCR could be used as a diagnostic tool to improve the accuracy of FNAB in both malignant and benign thyroid tissues. We extracted mRNA/DNA/proteins from fresh malignant and benign thyroid nodules using a QIAGEN DNA/RNA/Protein Kit. We ran isolated pure mRNA through Enigma-qPCR. The results showed that the Enigma-mRNA expression was 3-fold higher in malignant as compared to benign thyroid tissues. This finding supports our previous Enigma immunohistochemistry data and shows a relative quantitative difference in Enigma-mRNA expression level between malignant and benign thyroid nodules. We conclude that Enigma-RT-qPCR can be used to effectively determine malignancies in FNAB samples derived from thyroid nodules. This method could potentially enhance the diagnostic accuracy of indeterminate nodules and decrease diagnostic thyroidectomies and associated morbidity.
机译:甲状腺癌症发病率在全球范围内上升。虽然细针吸入活检(FNAB)是评估甲状腺结节的准确模态,但高达25%的FNAB仍然产生不确定的结果。由于不确定的FNAB,存在相当数量的良性疾病诊断甲状腺切除术。一种更准确和有效的分析不确定甲状腺结节的诊断方法可以减少诊断甲状腺切除术。最近,通过其与骨形态发生蛋白-1(BMP-1)的相互作用,骨质发生蛋白质,eniigma,eNigma已与不同的癌症类型有关,包括甲状腺癌进展和钙化,以及与促有丝发型信号传导途径连接的酪氨酸激酶[1,2] 。我们与免疫组织化学的Enigma蛋白分析的已发表数据显示,导致歧视恶性与良性甲状腺结节之间的鉴别,并证明与甲状腺癌阶段的相关性[3]。在这项研究中,我们通过实时(RT-QPCR)在基因表达水平下研究eniigma,这是一种定量和更少有效的方法,其需要比免疫组织化学更小的样品(FNA)。我们分析了eniigma mRNA表达水平以确定ENIGMA-QPCR是否可以用作诊断工具,以提高恶性和良性甲状腺组织中FNAB的准确性。我们使用QIAGEN DNA / RNA /蛋白质试剂盒从新鲜恶性和良性甲状腺结节中提取mRNA / DNA /蛋白。我们通过Enigma-QPCR跑了纯纯mRNA。结果表明,与良性甲状腺组织相比,恶性肿瘤中的雌激素表达较高3倍。这一发现支持我们以前的谜免疫组化数据,并显示了恶性和良性甲状腺结节之间的雌性-mRNA表达水平的相对定量差异。我们得出结论,Enigma-RT-QPCR可用于有效地确定来自甲状腺结节的FNAB样品中的恶性肿瘤。该方法可以提高不确定结节的诊断准确性,降低诊断甲状腺切除术和相关的发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号